Table 1.
Body weight, systolic blood pressure, and blood glucose.
| C (n = 14) |
C + DAPA (n = 14) |
DM (n = 20) |
DM + DAPA (n = 20) |
|
|---|---|---|---|---|
| Initial BW (g) | 448 ± 44 | 449 ± 44 | 450 ± 42 | 448 ± 39 |
| Final BW (g) | 507 ± 52 | 474 ± 50 | 381 ± 52 * | 430 ± 48 #§ |
| Final BP (mmHg) | 124 (122–127) | 123 (120–126) | 140 (136–144) * | 133 (130–138) #§ |
| Initial blood glucose (mg/dL) | 111 (106–115) | 103 (99–111) | 111 (104–114) | 105 (103–114) |
| Blood glucose before DAPA | 110 (102–113) | 108 (104–119) | 573 (443–600) * | 560 (439–600) # |
| Final blood glucose (mg/dL) | 101 (95–105) | 99 (90–109) | 494 (422–546) * | 145 (131–188) #§ |
Data are expressed as mean ± standard deviation or median and 25th and 75th percentiles. C: control; C + DAPA: control treated with dapagliflozin; DM: diabetes mellitus; DM + DAPA: DM treated with dapagliflozin; BW: body weight; BP: systolic blood pressure; Blood glucose before DAPA: blood glucose concentration after DM induction and before dapagliflozin treatment. ANOVA for a 2 × 2 factorial design and Tukey or Kruskal–Wallis and Dunn; * p < 0.05 vs. C; # p < 0.05 vs. C + DAPA; § p < 0.05 vs. DM.